Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724260 | 0.88 | ESR1 (0.50) | ESR1ESR2PPARDPPARASRD5A2 | |
| SCHEMBL13092162 | 0.74 | ADRA2A (0.53) | ESR1ESR2PPARDSRD5A2HTR6 | |
| SCHEMBL6641847 | 0.72 | FFAR1 (0.48) | ESR1ESR2PPARDPPARA | |
| SCHEMBL5640708 | 0.71 | PPARD (0.80) | PPARDPPARA | |
| SCHEMBL16193413 | 0.69 | CYP19A1 (0.45) | SRD5A2RXRARXRBRXRG | |
| SCHEMBL14378629 | 0.69 | PPARA (0.57) | ESR1ESR2PPARDPPARA | |
| SCHEMBL4819560 | 0.69 | PPARA (0.57) | ESR1ESR2PPARDPPARA | |
| SCHEMBL6840333 | 0.68 | ALOX5 (0.55) | — | |
| SCHEMBL21743513 | 0.68 | HDAC1 (0.55) | ESR1ESR2PPARD | |
| SCHEMBL29726906 | 0.68 | ALDH1A1 (0.50) | SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | disclosed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ESR1 2868/4885ESR2 2261/4885PPARD 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.